Clinical trials: PD-1 Antibodies
Breast Cancer
Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
This is a multi-center, prospective, interventional, single-arm clinical trial. In the study, patients with her2-positive recurrent or metastatic breast cancer who were initially treated were included.
- Trial name
- NCT05291910
- Testing
- Inetetamab, Toripalimab, Albumin-Bound Paclitaxel
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to look at the efficacy and safety of sintilimab in combination with carboplatin and nab-paclitaxel in patients with oral cavity or oropharyngeal squamous cell carcinoma who are about to undergo…
- Trial name
- OOC-001 (NCT04718415)
- Testing
- sintilimab, paclitaxel, carboplatin, Surgical resection
- Where
- 2 sites in China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Healthy Male Subjects
A Study to Evaluate the PK Similarity of AK112 in Healthy Chinese Male Subjects
The purpose of this study is to evaluate the pharmacokinetic (PK) similarity of AK112 (an anti-PD-1/VEGF bispecific antibody) from the proposed new manufacturing site and the approved original site in healthy male subjects.
- Trial name
- NCT07340476
- Testing
- AK112 (New Site), AK112 (Original Site)
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Akeso
Bladder Cancer
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Neoadjuvant chemotherapy plus radical cystectomy is the standard if care for cisplatin-eligible patients with MIBC. Developments in the last two decades suggest that bladder sparing therapy may be a valuable alternative to…
- Trial name
- NCT05531123
- Testing
- Tislelizumab, gemcitabine and cisplatin, Modified hypofractionation
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fudan University
Colorectal Cancer, Liver Metastases
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
To explore the efficacy and safety of stereotactic body radiation therapy (SBRT) combined with PD-1 monoclonal antibody in the treatment of unresectable colorectal cancer liver metastasis through a prospective study, providing…
- Trial name
- SPARKLE-L (NCT06794086)
- Testing
- Stereotactic body radiation therapy, PD-1 Monoclonal Antibody, Chemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Jun Huang
Pancreatic Adenocarcinoma Locally Advanced
Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
The study explores the efficacy and safety of cryoablation combined with the dual-function antibody PD-1/CTLA-4 (Apalulizumab) for the treatment of locally advanced pancreatic cancer following failure of first-line AG therapy.
- Trial name
- NCT07306286
- Testing
- Cryoablation, Dual-Function Antibody PD-1/CTLA-4
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Head and Neck Squamous Cell Carcinoma
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma…
- Trial name
- NCT06437522
- Testing
- BL-B01D1, PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
The purpose of this study is to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with programmed cell death protein-1 (PD-1) antibody compared with TACE Alone in patients with unresectable…
- Trial name
- NCT03782831
- Testing
- TACE, PD-1 antibody
- Where
- 3 sites in China
- Sponsor
- Sun Yat-sen University
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
This is a prospective, randomized, controlled Phase II clinical study designed to evaluate the efficacy and safety of adding Aitua Combination Antibody (a PD-1/CTLA-4 bispecific antibody) to standard neoadjuvant chemotherapy for…
- Conditions
- High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers, Primary Peritoneal Cancer
- Trial name
- NCT07432594
- Testing
- Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5)
- Volunteers
- 82 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Melanoma, Non Small Cell Lung Cancer
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody.
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, High Grade Serous Adenocarcinoma of Ovary
- Trial name
- PRESERVE-009 (NCT05858736)
- Testing
- AI-061
- Where
- 5 sites in Australia
- Volunteers
- 18 people
- Sponsor
- OncoC4, Inc.
Hepatocellular Carcinoma
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in patients with hepatocellular carcinoma resistant to PD-1 monoclonal…
- Trial name
- NCT06364800
- Testing
- γδ T cells, PD-1 monoclonal antibody, targeted drugs
- Volunteers
- 18 people
- Sponsor
- Beijing 302 Hospital
Hepatocellular Carcinoma
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria
- Trial name
- NCT03775707
- Testing
- Lenvatinib, PD-1 antibody
- Where
- China
- Sponsor
- Shi Ming
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
Metastatic Melanoma
Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
This is an open mono-centric prospective non-randomized study in patients with metastatic melanoma treated with Anti-PD1 monoclonal antibodies (Nivolumab).
- Trial name
- PAIR (NCT02626065)
- Testing
- blood sampling, Nivolumab
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Hospices Civils de Lyon
Chronic Hepatitis B
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.
- Trial name
- NCT06357806
- Testing
- Sintilimab, Peg-IFNα-2b, NAs
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Beijing 302 Hospital
Small Cell Lung Cancer Extensive Stage
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
This is a multicenter, open-label, Randomized, phase Ib/II clinical study to evaluate the anti-tumor efficacy, safety, tolerability, and PK of IN10018 in combination with anti-PD-1/L1 monoclonal antibody (Tislelizumab is proposed…
- Trial name
- NCT06030258
- Testing
- IN10018, Tislelizumab, Carboplatin
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Locally Advanced Rectal Cancer, Neoadjuvant Therapy
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
SERRAC is a prospective, multicentre, randomized phase II trial. 138 LARC (T3-4/N+M0, distance from anal verge ≤10cm) patients will be treated with neoadjuvant therapy and assigned to Group A and Group B (1:1).
- Trial name
- NCT07150949
- Testing
- Long-course radiotherapy, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma (HNSCC), HNSCC
Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma
Exploring the efficacy and safety of Tislelizumab combined with stereotactic body radiation therapy (SBRT) as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NEOSTART (NCT06673693)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Relapsed/Refractory Primary Central Nervous System Lymphoma
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
This study is a prospective, single-arm, open label, Phase Ib/II clinical study to evaluate the safety and efficacy of selinexor in combination with temozolomide and anti-PD-1 monoclonal antibody in patients with…
- Trial name
- NCT06556199
- Testing
- Selinexor, Temozolomide, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine